Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model

Lipids in Health and Disease

Elizeu A Rossi¹  Roseli A Pinto¹  Mariana N Roselino¹  Nadiége D Pauly-Silveira¹  Regina C Vendramini²  Dulcinéia SP Abdalla³  Juliana Y Suzuki¹  Daniela CU Cavallini¹ 

[1]Department of Food & Nutrition, School of Pharmaceutical Sciences, Sao Paulo State University, Araraquara, SP, Brazil

[2]Department of Clinical Analysis, School of Pharmaceutical Sciences, Sao Paulo State University, Araraquara, SP, Brazil

[3]Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil

关键词: lipid parameters;    fecal microbiota;    Enterococcus faecium CRL 183;    probiotics;   

Others  :  1212574
DOI  :  10.1186/1476-511X-10-126

 received in 2011-06-06, accepted in 2011-07-29,  发布年份 2011

【 摘 要 】

Background

Previous work showed that daily ingestion of an aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416, supplemented or not with isoflavones, reduced the total cholesterol and non-HDL-cholesterol levels, increased the high-density lipoprotein (HDL) concentration and inhibited the raising of autoantibody against oxidized low-density lipoprotein (ox-LDL Ab) and the development of atherosclerotic lesions.

Objective

The aim of this study was to characterize the fecal microbiota in order to investigate the possible correlation between fecal microbiota, serum lipid parameters and atherosclerotic lesion development in rabbits with induced hypercholesterolemia, that ingested the aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416.

Methods

The rabbits were randomly allocated to five experimental groups (n = 6): control (C), hypercholesterolemic (H), hypercholesterolemic plus unfermented soy product (HUF), hypercholesterolemic plus fermented soy product (HF) and hypercholesterolemic plus isoflavone-supplemented fermented soy product (HIF). Lipid parameters and microbiota composition were analyzed on days 0 and 60 of the treatment and the atherosclerotic lesions were quantified at the end of the experiment. The fecal microbiota was characterized by enumerating the Lactobacillus spp., Bifidobacterium spp., Enterococcus spp., Enterobacteria and Clostridium spp. populations.

Results

After 60 days of the experiment, intake of the probiotic soy product was correlated with significant increases (P < 0.05) on Lactobacillus spp., Bifidobacterium spp. and Enterococcus spp. and a decrease in the Enterobacteria population. A strong correlation was observed between microbiota composition and lipid profile. Populations of Enterococcus spp., Lactobacillus spp. and Bifidobacterium spp. were negatively correlated with total cholesterol, non-HDL-cholesterol, autoantibodies against oxidized LDL (oxLDL Ab) and lesion size. HDL-C levels were positively correlated with Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. populations.

Conclusion

In conclusion, daily ingestion of the probiotic soy product, supplemented or not with isoflavones, may contribute to a beneficial balance of the fecal microbiota and this modulation is associated with an improved cholesterol profile and inhibition of atherosclerotic lesion development.

【 授权许可】

   
2011 Cavallini et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, Ebbels T, De Iorio M, Brown IJ, Veselkov KA, Daviglus ML, Kesteloot H, Ueshima H, Zhao L, Nicholson JK, Elliott P: Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008, 453:396-400.
• [2]Kelly D, King T, Aminov R: Importance of microbial colonization of the gut in early life to the development of immunity. Mutat Res 2007, 622:58-69.
• [3]Goff DA, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, Bruce M, Psaty BM: Dyslipidemia Prevalence, Treatment, and Control in the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2006, 113:647-656.
• [4]Martínez I, Wallace G, Zhang C, Legge R, Benson AK, Carr TP, Moriyama EN, Walter J: Diet-induced metabolic improvements in a hamster model of hypercholesterolemia are strongly linked to alterations of the gut microbiota. Appl Environm Microbiol 2009, 75:4175-4184.
• [5]Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JL: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci 2004, 101:15718-15723.
• [6]Backhed F, Manchester JK, Semenkovich CF, Gordon JL: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci 2007, 104:979-984.
• [7]Rossi EA, Vendramini RC, Carlos IZ, Pei YC, Valdez GF: Development of a novel fermented soymilk product with potential probiotic properties. Eur Food Res Technol 1999, 209:305-307.
• [8]Rossi EA, Vendramini RC, Carlos IZ, Ueiji IS, Squinzari M, Silva SI, Valdez GF: Effects of a novel fermented soy product on the serum lipids of hypercholesterolemic rabbits. Arq Bras Cardiol 2000, 74:213-216.
• [9]Rossi EA, Vendramini CR, Carlos IZ, Oliveira MG, Valdez GF: Efeito de um novo produto fermentado de soja sobre lípides séricos de homens adultos normocolesterolêmicos. Arch Latinoam Nutr 2003, 53:47-51.
• [10]Rossi EA, Cavallini DCU, Carlos IZ, Vendramini RC, Damaso AR, Valdez GF: Intake of isoflavone-supplemented soy yogurt fermented with Enterococcus faecium lowers serum total cholesterol and non-HDL cholesterol of hypercholesterolemic rats. Eur Food Res Technol 2008, 228:275-282.
• [11]Cavallini DCU, Abdalla DSP, Vendramini RC, Bedani R, Bomdespacho LQ, Pauly-Silveira ND, Valdez GF, Rossi EA: Effects of isoflavone-supplemented soy yogurt on lipid parameters and atherosclerosis development in hypercholesterolemic rabbits: a randomized double-blind study. Lipids Health Dis 2009, 8:40. BioMed Central Full Text
• [12]Allain CA, Poon LS, Chan CSG, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 1974, 20:470-475.
• [13]Bergmeyer HW: Methods of enzymatic analysis. London: Academic Press; 1974:1890-1893.
• [14]Song T, Lee S-O, Murphy PA, Hendrich S: Soy protein with or without isoflavones, soy germ and soy germ extract, and daidzein lessen plasma cholesterol levels in golden syrian hamsters. Exp Biol Med 2006, 228:1063-1068.
• [15]Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM: Joint Distribution of Non-HDL and LDL Cholesterol and Coronary Heart Disease Risk Prediction Among Individuals With and Without Diabetes. Diabetes Care 2005, 28:1916-1921.
• [16]Damasceno NRT, Hiro G, Rodrigues FMD, Dias CTS, Okawabata FS, Abdalla DSP, Gidlund M: Soy protein isolate reduces the oxidizability of LDL and the generation of oxidized LDL autoantibodies in rabbits with diet-induced atherosclerosis. J Nutr 2000, 130:2641-2647.
• [17]Cavallini DCU, Pauly-Silveira ND, Abdalla DSP, Rossi EA: Effect of simvastatin on the generation of autoantibodies against oxidized LDL and progression of atherosclerosis in rabbits. Latin Am J Pharm 2010, 29:1419-1424.
• [18]Llera-Moya M, Rothblat GH, Glick JM, England JM: Etoposide treatment suppresses atherosclerotic plaque development in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1992, 12:1363-1370.
• [19]Edlund C, Beyer G, Hiemer-Bau M, Ziege S, Lode H, Nord CE: Comparative effects of moxifloxacin and clarithromycin on normal intestinal microflora. Scand J Infect Dis 2000, 32:81-85.
• [20]Yoshioka H, Iseki K, Fujita K: Development and difference of intestinal flora in the neonatal period in breast-fed and bottle-fed infants. Pediatrics 1993, 72:317-321.
• [21]Munoa FJ, Pares R: Selective medium for isolation and enumeration of Bifidobacterium spp. Appl Environ Microbiol 1988, 54:1715-1718.
• [22]Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D: Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001, 152:735-741.
• [23]Marzotto M, Maffeis C, Paternoster T, Ferrario R, Rizzotti L, Pellegrino M, Dellaglio F, Torriani S: Lactobacillus paracasei A survives gastrointestinal passage and affects the fecal microbiota of healthy infants. Res Microbiol 2006, 157:857-866.
• [24]Neish AS: Microbes in gastrointestinal health and disease. Gastroenterology 2009, 136:65-80.
• [25]Quigley EMM: Prebiotics and probiotics, modifying and mining the microbiota. Pharmacol Res 2010, 61:213-218.
• [26]Bedani R, Pauly-Silveira ND, Roselino MN, Valdez GF, Rossi EA: Effect of fermented soy product on the fecal microbiota of rats fed on a beef-based animal diet. J Sci Food Agric 2010, 90:233-238.
• [27]Bourlioux P, Koletzko B, Guarne F, Braesco V: The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium ''The Intelligent Intestine'', held in Paris, 14 June 2002. Am J Clin Nutr 2003, 78:675-678.
• [28]Mitsuoka T: Bifidobacteria and their role in human health. J Ind Microbiol 1990, 6:263-268.
• [29]Kinouchi FL: "Iogurte" de soja como coadjuvante no cancer de mama. PhD thesis. São Paulo State University, Clinical Analysis Department; 2006.
• [30]Sivieri K, Spinardi-Barbisan ALT, Barbisan LF, Bedani R, Pauly ND, Carlos IZ, Rossi EA: Probiotic Enterococcus faecium CRL 183 inhibit chemically induced colon cancer in male Wistar rats. Eur Food Res Technol 2008, 228:231-237.
• [31]Vendramini AP: Efeito da ingestão de um produto de soja fermentado com Enterococcus faecium e Lactobacillus helveticus na produção de citocinas, óxido nítrico e peróxido de nitrogênio. In Master degree dissertation. São Paulo State University, Clinical Analysis Department; 2002.
• [32]Steer T, Carpenter H, Tuohy K, Gibson GR: Perspectives on the role of the human gut microbiota and its modulation by pro- and prebiotics. Nutr Res Rev 2000, 13:229-254.
• [33]Fooks LJ, Gibson GR: Probiotics as modulators of the gut flora. Br J Nutr 2002, 88(S1):39-49.
• [34]Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R: Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
• [35]Bouhnik Y, Achour L, Paineau D, Riottot AA, Bournet F: Four-week short chain fructooligosaccharides ingestion leads to increasing fecal bifidobacteria and cholesterol excretion in healthy elderly volunteers. Nutr J 2007.
• [36]Nauruszewicz M, Johansson M-L, Zapolska-Downar D, Bukowska H: Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factor in smokers. Am J Clin Nutr 2002, 76:1249-1255.
• [37]Park YH, Kim JG, Shin YW, Kim HS, Kim YJ, Chun T, Kim SH, Whang KY: Effects of Lactobacillus acidophilus 43121 and a mixture of Lactobacillus casei and bifidobacterium longum on the serum cholesterol level and fecal sterol excretion hypercholesterolemia induced pigs. Biosci Biotechnol Biochem 2008, 72:595-600.
• [38]Xiao JZ, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A, Iwatsuki K, Kokubo S, Hosono A: Effects of milk products fermented by bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci 2003, 86:2452-2461.
• [39]Wang Y, Xu N, Xi A, Ahmed Z, Zhang B, Bai X: Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet. Appl Microbiol Biotechnol 2009, 84:341-347.
• [40]Rossi EA, Giori GS, Holgado APR, Valdez GF: In vitro effect of Enterococcus faecium and Lactobacillus acidophilus on cholesterol. Microbiologie-aliments-nutrition 1994, 12:267-270.
• [41]Saavedra L, Taranto MP, Sesma F, Valdez GF: Homemade traditional cheeses for the isolation of probiotic Enterococcus faecium strains. Int J Food Microbiol 2003, 88:241-245.
• [42]Pereira DIA, Gibson GR: Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol 2002, 68:4689-4693.
• [43]Zhao JR, Yang H: Progress in the effect of probiotics on cholesterol and its mechanism. Wei Sheng Wu Xue Bao 2005, 45:315-319.
• [44]Kimoto H, Ohmomo S, Okamoto T: Cholesterol removal from media by lactococci. J Dairy Sci 2002, 85:3182-3188.
• [45]St-Onge M-P, Farnworth ER, Jones PJH: Consumption of fermented and nonfermented dairy products: effects on cholesterol concentrations and metabolism. Am J Clin Nutr 2000, 71:674-681.
• [46]Begley M, Hill C, Gahan CGM: Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 2006, 72:1729-1738.
• [47]Wolever TMS, Spadafora PI, Eshuis H: Interation between colonic acetate and propionate in humans. Am J Clin Nutr 1991, 53:681-687.
• [48]Trautwein EA, Rieckhoff D, Erbersdobler HF: Dietary Inulin Lowers Plasma Cholesterol and Triacylglycerol and Alters Biliary Bile Acid Profile in Hamsters. J Nutr 1998, 128:1937-1943.
• [49]Duncan SH, Louis P, Flint HJ: Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environm Microbiol 2004, 70:5810-5817.
• [50]Meimandipou A, Shuhaimi M, Hair-Bejo M, Azhar K, Kabeir BM, Rasti B, Yazid AM: In vitro fermentation of broiler cecal content: the role of lactobacilli and pH value on the composition of microbiota and end products fermentation. Lett Appl Microbiol 2009, 49:415-420.
• [51]Craig W: Autoantibodies against oxidized low density lipoprotein: a review of clinical findings and assay methodology. J Clin Lab Anal 1995, 9:70-74.
• [52]Epstein SE, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D: Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol 2000, 20:1417-20.
• [53]Leahy SC, Higgins DG, Fitzgerald GF, Van Sinderen D: Getting better with bifidobacteria. J Appl Microbiol 2005, 98:1303-1315.